-
1
-
-
10844264628
-
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors
-
Amador M.L., et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res. 2004, 64:9139-9143.
-
(2004)
Cancer Res.
, vol.64
, pp. 9139-9143
-
-
Amador, M.L.1
-
2
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group
-
Fossella F., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 2003, 21:3016-3024.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3016-3024
-
-
Fossella, F.1
-
3
-
-
0012381722
-
Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer
-
Fukuoka M., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003, 21:2237-2246.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
-
4
-
-
24944503508
-
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer
-
Gandara D., et al. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin. Cancer Res. 2005, 11:5057s-5062s.
-
(2005)
Clin. Cancer Res.
, vol.11
-
-
Gandara, D.1
-
5
-
-
19844362355
-
Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer
-
Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J. Clin. Oncol. 2005, 23:3235-3242.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 3235-3242
-
-
Giaccone, G.1
-
6
-
-
39449096577
-
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving Gefitinib
-
Gregorc V., et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving Gefitinib. Clin. Pharmacol. Ther. 2008, 83:477-484.
-
(2008)
Clin. Pharmacol. Ther.
, vol.83
, pp. 477-484
-
-
Gregorc, V.1
-
7
-
-
33846994719
-
The impact of epidermal growth factor receptor gene status on Gefitinib-treated Japanese patients with non-small-cell lung cancer
-
Ichihara S., et al. The impact of epidermal growth factor receptor gene status on Gefitinib-treated Japanese patients with non-small-cell lung cancer. Int. J. Cancer 2007, 120:1239-1247.
-
(2007)
Int. J. Cancer
, vol.120
, pp. 1239-1247
-
-
Ichihara, S.1
-
8
-
-
19844375720
-
Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology
-
Janne P.A., Engelman J.A., Johnson B.E. Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 2005, 23:3227-3234.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 3227-3234
-
-
Janne, P.A.1
Engelman, J.A.2
Johnson, B.E.3
-
9
-
-
33846504706
-
A "silent" polymorphism in the MDR1 gene changes substrate specificity
-
Kimchi-Sarfaty C., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007, 315:525-528.
-
(2007)
Science
, vol.315
, pp. 525-528
-
-
Kimchi-Sarfaty, C.1
-
10
-
-
40949096067
-
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with Gefitinib
-
Liu G., et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with Gefitinib. Pharmacogenomics J. 2008, 8:129-138.
-
(2008)
Pharmacogenomics J.
, vol.8
, pp. 129-138
-
-
Liu, G.1
-
11
-
-
68949208058
-
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
-
Ma F., et al. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer 2009, 66:114-119.
-
(2009)
Lung Cancer
, vol.66
, pp. 114-119
-
-
Ma, F.1
-
12
-
-
74549114727
-
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
-
Mitsudomi T., Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 2010, 277:301-308.
-
(2010)
FEBS J.
, vol.277
, pp. 301-308
-
-
Mitsudomi, T.1
Yatabe, Y.2
-
13
-
-
35448992847
-
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer
-
Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007, 67:9609-9612.
-
(2007)
Cancer Res.
, vol.67
, pp. 9609-9612
-
-
Sauna, Z.E.1
Kimchi-Sarfaty, C.2
Ambudkar, S.V.3
Gottesman, M.M.4
-
14
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller J.H., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
-
(2002)
N. Engl. J. Med.
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
-
15
-
-
58949098405
-
Epidermal growth factor receptor intron-1 polymorphism predicts Gefitinib outcome in advanced non-small cell lung cancer
-
Tiseo M., et al. Epidermal growth factor receptor intron-1 polymorphism predicts Gefitinib outcome in advanced non-small cell lung cancer. J. Thorac. Oncol. 2008, 3:1104-1111.
-
(2008)
J. Thorac. Oncol.
, vol.3
, pp. 1104-1111
-
-
Tiseo, M.1
-
16
-
-
75749153247
-
Predictors of Gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
-
Tiseo M., et al. Predictors of Gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer 2010, 67:355-360.
-
(2010)
Lung Cancer
, vol.67
, pp. 355-360
-
-
Tiseo, M.1
-
17
-
-
69549123990
-
Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk
-
Yang M., et al. Functional FEN1 polymorphisms are associated with DNA damage levels and lung cancer risk. Hum. Mutat. 2009, 30:1320-1328.
-
(2009)
Hum. Mutat.
, vol.30
, pp. 1320-1328
-
-
Yang, M.1
|